BCL2L1 and Thrombocytopenia: Dual Bcl-2/BCL-XL antagonists such as navitoclax (ABT-263) are associated with dose-limiting thrombocytopenia, reflecting the dependence of platelets on BCL-XL for survival, which narrows the therapeutic window and complicates combination regimens [122,123,124].